Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dual Checkpoint Agonist x Antagonist
- Development stage
- Preclinical
- Lead developer
- Radiant Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
The Dual Checkpoint Agonist x Antagonist is a preclinical-stage therapeutic program developed by Radiant Biotherapeutics using its proprietary Multabody™ platform. This multi-specific engineered molecule is designed to modulate the immune system by simultaneously acting as an agonist at one immune checkpoint receptor and an antagonist at another. By leveraging the high-avidity and multi-targeting capabilities of the Multabody™ architecture, the drug aims to provide a sophisticated approach to immune regulation for the treatment of various immunological and inflammatory diseases. The specific checkpoint targets and lead indications within the immunology space remain undisclosed.
- Other names
- Checkpoint Agonist x Antagonist MultabodyDual Checkpoint Agonist x Antagonist (Radiant Biotherapeutics)
Beyond the preview
Go deeper on Dual Checkpoint Agonist x Antagonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dual Checkpoint Agonist x Antagonist.